Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference


IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upcoming SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET.

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501) 

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter 

Investor Contact: 

Stephen Jasper 
Gilmartin Group 
(858) 525-2047 
stephen@gilmartinir.com 

Source: Eledon Pharmaceuticals